ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim

Boehringer IngelheimThe European Respiratory Society (ERS) has announced that Dr Esther Barreiro, Municipal Institute of Medical Investigation/Hospital del Mar in Barcelona, Spain is this year's winner of the Society's annual award for research in the field of Chronic Obstructive Pulmonary Disease (COPD).

The ERS COPD Research Award recognises the work of young European ERS member active in pulmonology research and has been awarded for the eighth time this year. It is sponsored by Boehringer Ingelheim and consists of one sponsorship totalling 50,000 Euros to be used for scientific research projects in the field of COPD.

This year, the prize of 50,000 Euros goes to Esther Barreiro for her study of the specific role of oxidative stress in the respiratory and peripheral muscle dysfunction of COPD patients. Her research of these pathophysiological mechanisms provides the basis for future therapeutic strategies aimed at restoring muscle mass and function. Elucidation of the precise mechanisms will improve the quality of life and survival of COPD patients whereby oxidants modulate muscle proteolysis and apoptosis in the COPD muscle dysfunction appears to be of viral importance given its potential therapeutic implications in these patients.

Dr Barreiro obtained her MD degree at Universitat de Barcelona and became specialized in Respiratory Medicine after finishing the official Spanish residency training period. She began her research career in 1997 at IMIM-Hospital del Mar in Barcelona. She received her Master of Science degree from McGill University, Montreal, Canada, and one year later her PhD degree at Universitat Pompeu Fabra in Barcelona. In October 2001, she joined the IMIM-Hospital del Mar with the aim of investigating the specific roles played by oxidative stress and inflammation in the muscle dysfunction of patients with COPD. In 2004, she also became an Associate Professor of the Experimental Sciences and Health Department at Universitat Pompeu Fabra in Barcelona.

"The ERS is delighted to receive so many applications at such a high standard this year and wishes to thank all applicants for their contributions. In particular, we congratulate Esther Barreiro for her excellent work and extend our thanks to Boehringer Ingelheim, a leader in the research and treatment of COPD, for making this award possible," said Leonardo Fabbri, ERS President. "I would also like to take this opportunity to invite members to submit entries for next year's award."

European members of the ERS up to age 45 are eligible to apply for the award. The official online application form can be found on the ERS website, http://www.ersnet.org. The deadline for applications is 26 February 2009. Selection of the successful candidates will be made by the Scientific Committee of the ERS.

The European Respiratory Society
Founded in 1990, the European Respiratory Society (ERS) is a not-for-profit, international medical organisation with almost 9,000 members - scientists, doctors and allied health professionals, coming from over 100 countries. The Society's mission is to alleviate suffering from respiratory disease and to promote lung health through research, knowledge sharing, medical and public education, and working with patient organisations.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]